Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 1:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 13,457 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Chronic Graft-Versus-Host-Disease Clear all
Recruiting Phase 3 Interventional

A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)

NCT06615050
View directory record Official record
Conditions
Graft-versus-host Disease (GVHD)
Interventions
Tacrolimus (Tac), Methotrexate (MTX), Ruxolitinib (Rux), Cyclophosphamide, Mycophenolate mofetil (MMF)
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
30
States / cities
Palo Alto, California • San Francisco, California • Miami, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 15, 2026, 1:36 PM EDT
Completed Not applicable Interventional

Enhanced Kidney Follow-up for AKI Survivors in Care Transitions

NCT04505891
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Education, Education and follow-up
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 5, 2022 · Synced Oct 15, 2026, 1:36 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Analysis of Post-exertional Malaise Using a Two-day CPET in People With ME/CFS

NCT04026425
View directory record Official record
Conditions
Myalgic Encephalomyelitis, Chronic Fatigue Syndrome
Interventions
Two-day cardiopulmonary exercise test
Other
Lead sponsor
Ithaca College
Other
Eligibility
18 Years to 70 Years
Enrollment
173 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
3
States / cities
Torrance, California • Ithaca, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 7, 2023 · Synced Oct 15, 2026, 1:36 PM EDT
Completed Early Phase 1 Interventional

Prevention of Post Mastectomy With Intraoperative Ketamine

NCT03090776
View directory record Official record
Conditions
Pain, Postoperative, Post-Mastectomy Chronic Pain Syndrome
Interventions
Ketamine, Placebo saline
Drug · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 15, 2026, 1:36 PM EDT
Recruiting Not applicable Interventional

BioFLO for Respiratory Recovery in SCI

NCT06011876
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
Acute Intermittent Hypoxia (AIH), Acute Intermittent Hypercapnic-Hypoxia (AIHH), Sham AIH
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 70 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 15, 2026, 1:36 PM EDT
Completed Phase 3 Interventional

Improving Pain Management and Long Term Outcomes Following High Energy Orthopedic Trauma (Pain Study)

NCT01789216
View directory record Official record
Conditions
Orthopaedic Fractures
Interventions
NSAID, Gabapentinoids, placebo
Drug
Lead sponsor
Major Extremity Trauma Research Consortium
Other
Eligibility
18 Years to 80 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
17
States / cities
Miami, Florida • West Palm Beach, Florida • Indianapolis, Indiana + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Oct 15, 2026, 1:36 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Phase 1b/2 Study of Alvocidib Plus Decitabine or Azacitidine in Patients With MDS

NCT03593915
View directory record Official record
Conditions
Myelodysplastic Syndromes (MDS)
Interventions
Alvocidib Plus Decitabine (during dose escalation only) or Azacitidine
Combination Product
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
12
States / cities
Chicago, Illinois • Iowa City, Iowa • Baltimore, Maryland + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2023 · Synced Oct 15, 2026, 1:36 PM EDT
Not listed Phase 2 Interventional

Temsirolimus Adventitial Delivery to Improve Angiographic Outcomes Below the Knee (TANGO)

NCT02908035
View directory record Official record
Conditions
Chronic Limb Ischemia
Interventions
Temsirolimus, Saline
Drug
Lead sponsor
Mercator MedSystems, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
8
States / cities
Little Rock, Arkansas • Orange, California • Denver, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2020 · Synced Oct 15, 2026, 1:36 PM EDT
Terminated Phase 1 Interventional

Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

NCT02614508
View directory record Official record
Conditions
Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma
Interventions
Buparlisib, Ibrutinib, Ofatumumab
Drug · Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 3, 2019 · Synced Oct 15, 2026, 1:36 PM EDT
Completed Phase 1 Interventional

Ganciclovir Plus Arginine Butyrate in Treating Patients With Cancer or Lymphoproliferative Disorders Associated With the Epstein Barr Virus

NCT00006340
View directory record Official record
Conditions
Leukemia, Lymphoma, Precancerous Condition, Small Intestine Cancer
Interventions
arginine butyrate, ganciclovir
Drug
Lead sponsor
Boston Medical Center
Other
Eligibility
3 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2000
U.S. locations
3
States / cities
Indianapolis, Indiana • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 26, 2013 · Synced Oct 15, 2026, 1:36 PM EDT
Completed Phase 3 Interventional Results available

Tenofovir Disoproxil Fumarate (Tenofovir DF) Versus Emtricitabine/Tenofovir DF in Subjects Resistant to Lamivudine

NCT00737568
View directory record Official record
Conditions
Hepatitis B
Interventions
TDF, FTC/TDF, TDF Placebo, FTC/TDF Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
3
States / cities
Bradenton, Florida • Flushing, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 11, 2016 · Synced Oct 15, 2026, 1:36 PM EDT
Completed Phase 3 Interventional Results available

Extension in AS: Sustainability of Benefits, Safety and Tolerability

NCT01863732
View directory record Official record
Conditions
Spondylitis, Ankylosing
Interventions
Secukinumab, Placebo (Pbo)
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
5
States / cities
Portland, Oregon • Duncansville, Pennsylvania • Jackson, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Oct 15, 2026, 1:36 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine

NCT03832998
View directory record Official record
Conditions
Migraine
Interventions
Erenumab Dose 1, Erenumab Dose 2, Erenumab Dose 3, Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
6 Years to 17 Years
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
38
States / cities
San Diego, California • Aurora, Colorado • Colorado Springs, Colorado + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 15, 2026, 1:36 PM EDT
Completed No phase listed Observational

Early Detection and Management of Bronchiolitis Obliterans Syndrome Following Pediatric Hematopoietic Stem Cell Transplantation

NCT03072849
View directory record Official record
Conditions
Bronchiolitis Obliterans Syndrome
Interventions
Pulmonary function testing, FAM Therapy
Procedure · Drug
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
6 Years to 18 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Oct 15, 2026, 1:36 PM EDT
Completed No phase listed Observational

Kinetic Biomarker for Chronic Lymphocytic Leukemia Prognosis

NCT00481858
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Not listed
Lead sponsor
KineMed
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
5
States / cities
San Diego, California • Rochester, Minnesota • New Hyde Park, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2011 · Synced Oct 15, 2026, 1:36 PM EDT
Completed Not applicable Interventional Results available

Surgical Treatment of Post-surgical Mastectomy Pain Utilizing the Regenerative Peripheral Nerve Interface

NCT04530526
View directory record Official record
Conditions
Post-Mastectomy Chronic Pain Syndrome
Interventions
Regenerative Peripheral Nerve Interface
Procedure
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 15, 2026, 1:36 PM EDT
Completed Phase 3 Interventional Results available

A Study to Investigate the Effect of Delayed Release Pancrelipase on Maldigestion in Patients With Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis and Pancreatectomy

NCT00414908
View directory record Official record
Conditions
Chronic Pancreatitis, Pancreatectomy, Pancreatic Exocrine Insufficiency
Interventions
Pancrelipase delayed release capsule, Placebo Comparator
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
23
States / cities
Scottsdale, Arizona • Bristol, Connecticut • Tampa, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2011 · Synced Oct 15, 2026, 1:36 PM EDT
Completed Not applicable Interventional

Intramuscular Electrical Stimulation for the Treatment of Trigger Points in Patients With Migraine

NCT05893914
View directory record Official record
Conditions
Chronic Migraine
Interventions
Dry Needling and intramuscular electrical stimulation to trigger points
Procedure
Lead sponsor
Thomas W. Perreault, PT
Other
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Dover, New Hampshire
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Oct 15, 2026, 1:36 PM EDT
Completed Not applicable Interventional

Chronic Low Back Pain Graded - Exposure Psychoeducation Intervention

NCT03909048
View directory record Official record
Conditions
Chronic Low Back Pain
Interventions
Interactive - Psychoeducation, Non-interactive Psychoeducation
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 31, 2019 · Synced Oct 15, 2026, 1:36 PM EDT
Completed Phase 3 Interventional

To Evaluate the Long-term Safety of (R,R)-Formoterol in Subjects With COPD

NCT00064415
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Chronic Bronchitis, Emphysema
Interventions
arformoterol, Salmeterol
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
35 Years and older
Enrollment
799 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
90
States / cities
Anniston, Alabama • Birmingham, Alabama • Jasper, Alabama + 77 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Oct 15, 2026, 1:36 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Establishing Clinical Utility for a New Diagnostic Test for Patients With Shortness of Breath

NCT04693793
View directory record Official record
Conditions
Dyspnea, Unexplained Chronic Dyspnea
Interventions
Education Materials and Janssen Test
Other
Lead sponsor
Qure Healthcare, LLC
Industry
Eligibility
Not listed
Enrollment
219 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 7, 2023 · Synced Oct 15, 2026, 1:36 PM EDT
Completed Phase 3 Interventional Results available

A follow-on Safety Study in Subjects With Crohn's Disease Who Have Previously Been Withdrawn From the Double-blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] Due to an Exacerbation of Crohn's Disease

NCT00160706
View directory record Official record
Conditions
Crohn's Disease
Interventions
Certolizumab Pegol (CDP870)
Biological
Lead sponsor
UCB Pharma SA
Industry
Eligibility
18 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
41
States / cities
Birmingham, Alabama • Huntsville, Alabama • Little Rock, Arkansas + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Oct 15, 2026, 1:36 PM EDT
Recruiting Phase 2 Interventional

Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)

NCT05536349
View directory record Official record
Conditions
Leukemia
Interventions
Pirtobrutinib, Obinutuzumab, Venetoclax, Valacyclovir, Allopurinol
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 15, 2026, 1:36 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Spatiotemporal Thalamocortical Alterations Underlie Experimental and Chronic Pain

NCT05763758
View directory record Official record
Conditions
Experimental Pain, Low Back Pain
Interventions
No intervention
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
2
States / cities
Tallahassee, Florida • Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 15, 2026, 1:36 PM EDT